ClinicalTrials.Veeva

Menu

Adipose Stem Cell Mitochondria Supplementation to Oocytes (ASCENT)

S

Sunkaky Medical Cooperation

Status

Enrolling

Conditions

Female Infertility
Mitochondria
Oocyte Competence
Recurent Implantation Failures
Advanced Age

Treatments

Other: Experimental

Study type

Interventional

Funder types

Industry
Other

Identifiers

NCT07066267
WishREC/24-011

Details and patient eligibility

About

The purpose of this study is to investigate the potential of autologous adipose stem cell (ASC) mitochondrial transfer (ASCENT) to oocytes along with intracytoplasmic sperm injection (ICSI)as a means of enhancing embryo development and improving the success rate of in patients with a history of multiple IVF failures. Embryo quality plays a crucial role in determining the success of assisted reproductive technologies and directly contributes to repeated pregnancy failures. Several factors, including age, physiological conditions, genetics, and environmental influences, can significantly impact embryo quality. Oocytes, the largest cells in the human body, are heavily reliant on mitochondria. Mitochondria's role in providing energy for oocytes is crucial, and insufficient energy production has been linked to poor oocyte and embryo quality. Some human studies have shown that increasing oocyte mitochondrial mass can improve embryo quality in patients who have experienced repeated IVF failures.

Full description

Sibling mature oocytes will be randomly divided into two groups. And one group of oocytes will be undergone conventional intracytoplasmic sperm injection (ICSI) (control group; cont. ICSI) and the other group of oocytes will be undergone mitochondria transplantation along with intracytoplasmic sperm injection (Mito-ICSI). Viable blastocysts from both groups will be biopsied for preimplantation genetic testing for aneuploidy.

Enrollment

20 estimated patients

Sex

Female

Ages

29 to 39 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Having at least three previous failed IVF trial
  • Specifically consented for to collect biopsies for Preimplantation generic testing for aneuploidy (PGTA) analysis
  • Specifically consented for to have single blastocyst transfer (recommended)
  • No major uterine or ovarian abnormalities
  • Specifically consented for to have all embryos frozen
  • Specifically consented for to collect adipose tissues from subcutaneous liposuction
  • BMI level level <26kg/m2

Exclusion criteria

  • Ovarian endometriosis with Chocolate cysts (American Fertility Society (AFS)) classification type 3 and 4
  • Any medical contraindication oocyte retrieval or subsequent procedures Ovarian hyperstimulation syndrome Bleeding disorders Sex hormone allergies Severe emotional defect on injections
  • Severe sperm abnormalities
  • <5 million/mL motile sperm
  • Uterine structural anomalies
  • Polycystic ovaries
  • Premature ovarian failure

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

20 participants in 2 patient groups

Autologous Mitochondria transfer
Active Comparator group
Description:
Mitochondria isolated from autologous adipose-derived stem cells are transplanted into the oocyte in conjunction with intracytoplasmic sperm injection (ICSI); Mito-ICSI group
Treatment:
Other: Experimental
Conventonal Intracytoplasmic Sperm Injection
No Intervention group
Description:
Conventional ICSI; Control group

Trial contacts and locations

1

Loading...

Central trial contact

Dr. HELARUWAN PASAN KUMARA WA, MD, PhD; Dr. SANATHUDAYANGA KANKANAMGAMAGE, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems